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ABSTRACT: The recent outbreak of coronavirus infectious disease 2019
(COVID-19) has gripped the world with apprehension and led to a scare of
epic proportions related to its potential to spread and infect humans worldwide. As
we are in the midst of an ongoing near pandemic outbreak of COVID-19, scientists
are struggling to understand how it resembles and varies with the severe acute
respiratory syndrome coronavirus (SARS-CoV) at the genomic and transcriptomic
level. In a short time following the outbreak, it has been shown that, similar to
SARS-CoV, COVID-19 exploits the angiotensin-converting enzyme 2 (ACE2)
receptor to gain entry inside the cells. This ﬁnding raises the curiosity of
investigating the expression of ACE2 in neurological tissue and the possible
contribution of neurological tissues damage to the morbidity and mortality of
COIVD-19. Here, we investigate the density of the expression levels of ACE2 in
the CNS and the host−virus interaction and relate it to the pathogenesis and
complications seen in recent cases of the COVID-19 outbreak. Also, we debate the need for a model of staging COVID-19 based on
neurological tissue involvement.
KEYWORDS: Coronavirus, COVID-19, tissue distribution, host−virus interaction, proposed mechanisms
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3. THE TISSUE DISTRIBUTION OF ACE2 IN HUMAN
ORGANS AND TISSUES
In order to discover the neurological pathogenic potential of
COVID-19 and relate it to neurological tissue expression of
ACE2, data retrieval was done from human protein databases.
Most of the evidence of ACE2 expression in the brain (Figure
1) comes from literature and mammalian tissue expression
databases,2 which prompted us to investigate neurotropic
eﬀects of COIVD-19 and its contribution toward the morbidity
and mortality of patients with COVID-19.
3.1. Evidence of the Distribution of ACE2 in the
Human Brain. The brain has been reported to express ACE2
receptors (Figure 1A, C) that have been detected over glial
cells and neurons, which makes them a potential target of
COVID-19. Previous studies have shown the ability of SARSCoV to cause neuronal death in mice by invading the brain via
the nose close to the olfactory epithelium.3 The contribution of

The ﬁrst reports of a viral infection attracted attention in late
December 2019 in Wuhan, the capital of Hubei, China. Later,
it was revealed that the virus responsible for causing the
infections was contagious between humans. In early January,
the terms like “the new coronavirus” and “Wuhan coronavirus”
were in common use. On February 11, 2020, a taxonomic
designation “severe acute respiratory syndrome coronavirus 2″
(SARS-CoV-2) became oﬃcial in order to refer to the virus
strain, that was previously termed as 2019-nCoV and Wuhan
coronavirus. Within a few hours on the same day, the WHO
oﬃcially renamed the disease as COVID-19.

2. THE GENOME OF THE COVID-19 VIRUS
32
33
34
35
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37

The complete genome of COVID-19 virus from Wuhan, China
was submitted on January 17, 2020 in the National Center for
Biotechnology1 (NCBI) database, with ID NC_045512. It is a
29,903 bp single-stranded RNA (ss-RNA) coronavirus. It has
now been shown that COVID-19 is a SARS-like coronavirus
that had previously been reported in bats in China.
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Figure 1. Tissue distribution of ACE2 receptors in humans. Viremia (A) disseminates the COVID-19 virus throughout the body via the
bloodstream (B). Neurotropism may occur via circulation that enables the COVID-19 to reach the brain (C) and bind and engage with the ACE2
receptors (D, blue). COVID-19 docks on the ACE2 via spike protein (D, golden spikes). Shown are lungs, heart, kidneys, intestines, brain, and
testicles that are well-known to express ACE2 receptors and are possible targets of COVID-19.
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neural targeting of COVID-19 in patients reported in the
recent outbreak remains to be established. In the SARS-CoV
infections reported in the past, autopsy ﬁndings of the patients
have shown the evidence-based presence of SARS-CoV via
electron microscopy, immunohistochemistry, and real-time
reverse transcription-PCR 3. Patients with acute SARS-CoV
illness have also shown the presence of the virus in
cerebrospinal ﬂuid. The role of the blood-brain barrier in
containing the virus and preventing it from gaining access to
the neural tissues needs to be further explored in COVID-19.
Recently, a study posted in medRxiv4 has reported neurological
manifestations in COVID-19 in the current outbreak that
involved 214 patients, of which 78 (36.4%) patients had
neurologic manifestations, which aﬃrms our rationale of the
neurotropic potential in the COVID-19 virus. Also, a ﬁnding
published on a patient who had loss of involuntary control over
breathing5 during the recent outbreak implores healthcare
professionals and clinicians to segregate COVID-19 patients
into neurologically aﬀected cases and those who are devoid of
neurological deﬁcits.

may be the reason for the higher binding aﬃnity of the
COVID-19 spike protein to the human ACE2 receptor.
Homology modeling of COVID-19 RBD subdomain-1 (319th
to 591st aa) in the SWISS-MODEL automated server
developed a template-based model of the 2019-nCoV
(COVID-19) spike glycoprotein with a single receptor-binding
domain up conﬁguration (Figure 2A1) with 100% sequence
identity. Of the other template-based models developed, it
expectedly showed a model of the structure of the SARS-CoV
spike glycoprotein, conformation 2 with about 74% sequence
identity (Figure 2B, B1), which shows them to be structurally
and evolutionarily related.

5. A PROPOSED CASCADE OF CEREBRAL
INVOLVEMENT IN THE COVID-19 INFECTIONS
The dissemination of COVID-19 in the systemic circulation or
across the cribriform plate of the ethmoid bone (Figure 1)
during an early or later phase of the infection can lead to
cerebral involvement as has been reported in the past for
SARS-CoV aﬀected patients.3 The presence of COVID-19 in
general circulation understandably enables them to pass into
the cerebral circulation (Figure 1A−C) where the sluggish
movement of the blood within the microcirculation could be
one of the factors that could facilitate the interaction of the
COVID-19 virus with ACE2 expressed in the capillary
endothelium. Subsequent budding of the viral particles from
the capillary endothelium and damage to the endothelial lining
can favor viral access to the brain (Figure 1B). Other possible
mechanisms like the transendothelial migration of the virus can
also enable virus entry into the brain. Once with the milieu of
the neuronal tissues, its interaction with ACE2 receptors
(Figure 1C, D) expressed in neurons2 can initiate a cycle of
viral budding accompanied by neuronal damage without
substantial inﬂammation as has been seen with cases of
SARS-CoV3 in the past. It is important to mention here that,
long before the proposed anticipated neuronal damages occur,
the endothelial ruptures in capillaries accompanied by bleeding

4. HOST−VIRUS INTERACTION: HOW THE ACE2
RECEPTOR IS EXPLOITED BY THE COVID-19 VIRUS
TO GAIN ENTRY INSIDE THE HOST CELLS
With the mRNA encoding 12 proteins,1 the COVID-19 virus,
like SARS-CoV, uses a spike protein S1 that enables the
attachment of the virion to the cell membrane by interacting
with host ACE2 receptor3,6 (Figure 1C, D). In the later study,6
it was shown that the ACE2 binding aﬃnity of the 2019-nCoV
spike protein ectodomain was 10−20-fold higher than ACE2
binding to SARS-CoV spike protein. A BLASTp search of the
COVID-19 RBD subdomain-1 (319th to 591st aa) fetched a
spike glycoprotein [bat coronavirus RaTG13] and S1 protein
and partial [SARS coronavirus GD322] as a homologue.
Pairwise sequence alignments of the three sequences show that
though the spike proteins of all three CoV are highly similar,
they are not identical (Figure 2A, horizontal arrows), which
B
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Figure 2. (A) Sequence alignment of COVID-19 RBD subdomain-1 (319th to 591st) amino acid (top row) with the bat and SARS-CoV spike
protein (middle and bottom row) that were fetched by BLASTp results of COVID-19 RBD subdomain-1 (319th to 591st) amino acids. Note
horizontal arrows that show areas of contrast. (A1) The homology modeling of COVID-19 RBD subdomain-1 (319th to 591st) amino acid
developed a template (6vsb.1. A)-based model of the 2019-nCoV (COVID-19) spike glycoprotein with a single receptor-binding domain up
conﬁguration. (B). Homology modeling of COVID-19 RBD subdomain-1 (319th to 591st) amino acid developed a template-(5x5b.1.A) based
model of the prefusion structure of SARS-CoV spike glycoprotein in conformation 2 (B1) with 73.96% sequence identity. [Uniprot and SWISSMODEL automated server were used for sequence alignments and development of the templates and models, respectively.]
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within the cerebral tissue can have fatal consequences in
patients with COIVD-19 infections. The movement of the
COVID-19 virus to the brain via the cribriform plate close to
the olfactory bulb can be an additional pathway of the virus to
aﬀect the brain, and ﬁnding of an altered sense of smell or
hyposmia in an uncomplicated early stage COVID-19 patient
should be investigated thoroughly for CNS involvement.

dysregulation sets in. Access of COVID-19 to the brain via the
transcribrial route, as described previously for other CNS
targeting pathogens,7 appears to be the case in a recently
reported patient with hyposmia,5 which needs to be further
investigated by attempting to isolate the COVID-19 virus from
zones in proximity to the olfactory bulb. The diﬀerences in the
spike proteins of COVID-19 and SARS-CoV (Figure 2A) may
enable scientists to exploit the contrast in sequences in order to
identify epitopes in COVID-19 for the development of
monoclonal antibodies against this virus. With the recent
COVID-19 outbreak, there is an urgent need to understand the
neurotropic potential of the COVID-19 virus in order to
prioritize and individualize the treatment protocols based on
the predominant organ involvement. Also, a staging system
based on the severity and organ involvement is needed for
COVID-19 in order to rank the patients for aggressive or
conventional treatment modalities.

6. CONCLUSIONS AND FUTURE DIRECTIONS
Autopsies of the COVID-19 patients, detailed investigation,
and attempts to isolate COVID-19 from the endothelium of
cerebral microcirculation, cerebrospinal ﬂuid, glial cells, and
neuronal tissue can clarify the role played by this novel
COVID-19 coronavirus in the mortalities observed in the
recent outbreak. It is important to mention here that though
the cerebral damage may complicate a COVID-19 infection, it
appears that it is the widespread dysregulation of the
homeostasis caused by pulmonary, renal, cardiac, and
circulatory damage that proves fatal in COIVD-19 patients.
With that being said, a dominant cerebral involvement alone
with the potential of causing cerebral edema in COVID-19 can
take a lead in causing death long before systemic homeostatic
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